Skip Navigation


JAC Advance Access originally published online on April 1, 2008
Journal of Antimicrobial Chemotherapy 2008 62(1):206-208; doi:10.1093/jac/dkn140
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/1/206    most recent
dkn140v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Walkty, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walkty, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study

Andrew Walkty1,*, Melanie DeCorby2, Kim Nichol1, James A. Karlowsky1, Daryl J. Hoban1,2, George G. Zhanel on behalf of the Canadian Antimicrobial Resistance Alliance (CARA)1,2

1 Departments of Medicine and Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada 2 Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

* Corresponding author. Tel: +1-204-453-3867; Fax: +1-204-787-4699; E-mail: awalkty@mts.net

Keywords: antimicrobial resistance , susceptibility , cefepime

The first 10% of the full text of this article appears below.

Sir,

In recent years, Pseudomonas aeruginosa isolates resistant to multiple classes of antimicrobial agents have become increasingly common.1 Several mechanisms may contribute to antimicrobial resistance among P. aeruginosa, including the production of a chromosomally encoded AmpC β-lactamase.1 Ceftobiprole (BAL9141), an investigational pyrrolidinone cephalosporin, is reported to have activity against a broad spectrum of clinically important Gram-negative bacteria including P. aeruginosa.2 Additionally, in vitro studies have demonstrated that ceftobiprole . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?